HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. - Wikidata - wikimedia - TriplyDB

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

http://www.wikidata.org/entity/Q39740926

about

CD36: implications in cardiovascular disease Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda.The Role of Caveolin 1 in HIV Infection and Pathogenesis.Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress.Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross-sectional study C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells.Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.HIV protease inhibitors and atherosclerosis HIV-1 Nef impairs key functional activities in human macrophages through CD36 downregulation.IgM colocalises with complement and C reactive protein in infarcted human myocardium.Gender-specific effects of HIV protease inhibitors on body mass in mice.Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy HIV-1 Nef in macrophage-mediated disease pathogenesis.State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.Inflammation, immune activation, and cardiovascular disease in HIV.Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection.Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.Prevention of atherosclerosis in patients living with HIV.HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.Cardiovascular effects of noncardiovascular drugs.The Relationship Between HIV Infection and Cardiovascular Disease.Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells.Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling.The spectrum of atherosclerotic coronary artery disease in HIV patients.Vitamin E-drug interactions: molecular basis and clinical relevance.HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

P2860

Q24678338-F9943F30-0DEE-414A-80E4-24493650CE04 Q24802369-B2FDE1E7-06F2-4E08-A67A-9FA66FAE257E Q26862601-24A65D71-4888-4CBE-A2F9-F1B6EBDAC6AE Q27318414-ECEF0BDA-CEA1-4B70-9CB0-A254691AC7C6 Q28386344-487141BF-D81F-40B2-9A6F-2E974AF71E7D Q28582686-B800E62C-7C09-48BA-8657-28824A715103 Q30278586-4A0CB7C8-1386-44AF-B97F-69CFA3A76FA7 Q32183747-BDEF3655-4216-464D-B82A-7D4358CDAED8 Q33262244-55D37EE6-FCBE-4CAF-BC26-38B8581B71F9 Q33604765-A9BCD01C-9E20-438B-BC42-4C3F8C80A92B Q33641499-99C81FFB-9E05-496B-9D79-1F1D304C06E4 Q33811250-60709189-3D0D-4B82-8544-DB321C480042 Q34082954-967A0C0A-48F3-4336-86E0-DAE5B58E5D52 Q34292033-0E079781-F0C8-4D61-9FD5-6304F4654E36 Q34335180-4DC4174B-3195-4DB5-9B23-89DD4A9D7A54 Q35060359-72C37C9C-9377-4EBE-A8EE-3928CE6B21DE Q35140300-3905BCCA-4891-4930-BE8E-C6C42457DE69 Q35588500-908EA3EB-5548-454B-8532-EA430A5010E5 Q35793960-86F36FF6-AA2C-4569-9095-2A2A485AAA89 Q35928192-2D2A3767-3B7F-427F-B596-8335F8915042 Q36011828-1FAF0F40-2AC2-4F8B-B9C6-F96D6187078B Q36512579-E4D5CDD1-5311-448A-A452-EA587BD1721E Q36531107-49D8A963-4265-42B8-ABCD-49D7B1E27B47 Q36812073-AC7AE5A3-835F-41B6-8B7B-2153C35F1689 Q36951676-49FB0F57-ABA2-4318-BD7D-D1B4DE7384F7 Q36957752-CD9C4667-CDF1-4B8E-ADB3-43971F515054 Q37033675-C3305454-ECEE-4BCE-B368-F3AE02DAD2C9 Q37134748-D2AC7498-4076-4C61-9048-50A03CA5E4B8 Q37150744-E3FDB5B2-3619-480A-9DC6-833604BEBF49 Q37162243-60C8B967-2A6E-442C-8532-F5E992641EA2 Q37167541-7F9FF817-CEE2-49F8-A7F1-7C9B7CD9083F Q37246875-BA3DD318-7FCA-4726-977C-028487999D88 Q37413163-FEB78F38-B2AE-46DB-8D70-222C5B5CD57A Q37429096-C719D775-B9EA-45AE-8681-273B60D7945E Q37455285-0E75824F-8E3B-424F-BBF6-F37C934E8BF3 Q37476547-B8345B8C-6056-45C2-BC30-5447388D1B67 Q37738331-946B4F0D-9C4F-4203-B641-2F6CCBCE5D9E Q38250082-852A2F5E-8B8F-4C57-B762-620420EB962E Q38649363-9B5450EC-DF98-45C4-8C78-30AFEBE6D857 Q38946641-C7D636BE-E0F3-4BC1-9089-67F19C3925CD

P2860

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

http://www.wikidata.org/entity/Q39740926

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

HIV protease inhibitors promot ...... r accumulation in macrophages.

@en

HIV protease inhibitors promot ...... r accumulation in macrophages.

@nl

type

label

HIV protease inhibitors promot ...... r accumulation in macrophages.

@en

HIV protease inhibitors promot ...... r accumulation in macrophages.

@nl

prefLabel

HIV protease inhibitors promot ...... r accumulation in macrophages.

@en

HIV protease inhibitors promot ...... r accumulation in macrophages.

@nl

P1433

Q39740926-C0C466D3-7D03-495E-9C83-96F0C88426C7

P1476

Q39740926-E5114C9B-2F42-4476-9060-1938E853F078

P2093

Q39740926-17EDB4F4-6EBF-4673-AB42-64AFD74888CB

Q39740926-25061020-A158-4500-8230-1117040169F7

Q39740926-2C08C74E-A06F-4F97-853A-1E0913B271B5

Q39740926-2FA16EBA-CC90-46B6-9AD6-DFAB9E419071

Q39740926-436EEEE6-3BD5-4DCD-8CB2-ECB0AD6252E1

Q39740926-45C1C1E8-F8FA-402E-9A9B-AF92663D3417

Q39740926-652DA2A5-328E-4641-A232-1E1E92698E1A

Q39740926-6E6E6CD8-F22F-47C1-9472-1C330403F2B4

Q39740926-8A85F5D5-6BA8-4D02-899C-244F4D56509F

Q39740926-97BF44DB-ED1E-430E-9232-4B647C1EF50E

P2860

Q39740926-02FFE598-0AA7-4A2B-8CB4-66A8892788C1

Q39740926-05988507-A814-41E6-8C99-CA974B0BCF14

Q39740926-1A398A4C-751A-447C-8B46-8E2CC8E4DC7A

Q39740926-1BF28ED9-3089-4880-B878-F4D1E17DB8F7

Q39740926-28A934AE-B6AE-498C-9BF6-D7815E928977

Q39740926-2F9339E9-E41D-4C4F-B6EA-B92B75D867D2

Q39740926-34DA85AF-3FD6-43C1-BA46-96E96442D5E1

Q39740926-38129C2C-F136-4F05-ACB3-364E261007CA

Q39740926-3D2CD88E-ACF5-4D27-9377-BD65ACF5884A

Q39740926-3E8A9628-0883-4E9D-908D-BDAC2C3E6C7B

P304

Q39740926-43DF6344-3E40-495B-B2E1-E4196F9C78B7

P31

Q39740926-5FAB6250-005A-4722-B103-FC17B7532DE3

P356

Q39740926-B936ADCC-1138-4F62-8EDE-38C90288FD10

P407

Q39740926-14B7F7D0-292F-4269-8F47-58863E150FD6

P433

Q39740926-DF6FFCCF-088B-4633-B6FB-D95FADA25A79

P478

Q39740926-3C777497-D984-410E-B6E5-64B28F6EEB78

P577

Q39740926-3C7930A3-C3DA-447C-80D2-FF01B03C8819

P698

Q39740926-50FEAEBB-BD66-46E9-B95A-B382A83BAEDD

P921

Q39740926-16356464-91AA-4BD1-AA36-8906B7A47A49

Q39740926-495D4A96-CDDC-4002-BC7D-FE11B6CBDCB4

Q39740926-5F17CBFD-FEDA-45A8-B04D-AF394F02E406

Q39740926-F355B148-8485-41D0-9F6C-EC4BDA387B14

P932

Q39740926-50590EAA-0B6D-4AF8-B1B0-10D05A0446C0

P356

P1433

Journal of Clinical Investigation

P1476

HIV protease inhibitors promot ...... r accumulation in macrophages.

@en

P2093

Annette Uittenbogaard

http://www.w3.org/2001/XMLSchema#string

David Meade

http://www.w3.org/2001/XMLSchema#string

Eric J Smart

http://www.w3.org/2001/XMLSchema#string

James Dressman

http://www.w3.org/2001/XMLSchema#string

Jeanie Kincer

http://www.w3.org/2001/XMLSchema#string

Ling Guo

http://www.w3.org/2001/XMLSchema#string

Melinda E Wilson

http://www.w3.org/2001/XMLSchema#string

Richard N Greenberg

http://www.w3.org/2001/XMLSchema#string

Sergey V Matveev

http://www.w3.org/2001/XMLSchema#string

Theresa Guerin

http://www.w3.org/2001/XMLSchema#string

P2860

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

Large variations in human foam cell formation in individuals: a fully autologous in vitro assay based on the quantitative analysis of cellular neutral lipids.

A rapid method to isolate platelets from human blood by density gradient centrifugation.

Macrophage scavenger receptors and foam cell formation.

Changing concepts of atherogenesis.

Biology of arterial atheroma.

An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.

P304

389-397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI200316261

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12569165

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

151854

http://www.w3.org/2001/XMLSchema#string